PA
ACRS icon

Profund Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Profund Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-13,098
Closed -$89.7K – 1128
2023
Q3 		$89.7K Buy
+13,098
New +$112K 0.01% 941
2023
Q2 		– Sell
-13,869
Closed -$112K – 1069
2023
Q1 		$112K Buy
+13,869
New +$176K 0.01% 1055
2019
Q1 		– Sell
-14,711
Closed -$109K – 1212
2018
Q4 		$109K Buy
14,711
+394
+3% +$4.06K 0.01% 1098
2018
Q3 		$208K Buy
+14,317
New +$245K 0.01% 1428

Other funds holding ACRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Profund Advisors's ACRS Position: Q4 2023 in Review

Profund Advisors sold out of Aclaris Therapeutics (ACRS) in Q4 2023, closing a stake of 13,098 shares — an estimated $89.7K sold.

Profund Advisors first reported a position in ACRS in Q3 2018 and held it in 4 quarters. The position peaked at $208K in Q3 2018. 107 funds tracked by Wall St. Rank hold ACRS as of Q4 2023.

  • Profund Advisors reported no remaining Aclaris Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Profund Advisors sold 13,098 Aclaris Therapeutics shares in Q4 2023, an estimated $89.7K.
  • Profund Advisors first reported a position in Aclaris Therapeutics in Q3 2018 and held it in 4 quarters.
  • Profund Advisors's Aclaris Therapeutics position peaked at $208K in Q3 2018.
  • 107 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2023.

Based on Profund Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.